Last reviewed · How we verify
TQC3721 suspension for inhalation
TQC3721 suspension for inhalation is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD).
TQC3721 suspension for inhalation is a medication that targets the respiratory system to treat a specific condition.
TQC3721 suspension for inhalation is a medication that targets the respiratory system to treat a specific condition. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | TQC3721 suspension for inhalation |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of TQC3721 is not publicly available, but it is believed to work by affecting the respiratory system to alleviate symptoms of a particular disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Cough
- Dyspnea
- Pharyngitis
Key clinical trials
- Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- A Phase II Clinical Trial of TQC3721 Suspension for Inhalation (PHASE2)
- A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. (PHASE2)
- A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)
- A Clinical Trial of TQC3721 Suspension for Inhalation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQC3721 suspension for inhalation CI brief — competitive landscape report
- TQC3721 suspension for inhalation updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about TQC3721 suspension for inhalation
What is TQC3721 suspension for inhalation?
How does TQC3721 suspension for inhalation work?
What is TQC3721 suspension for inhalation used for?
Who makes TQC3721 suspension for inhalation?
What development phase is TQC3721 suspension for inhalation in?
What are the side effects of TQC3721 suspension for inhalation?
Related
- Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: TQC3721 suspension for inhalation vs similar drugs
- Pricing: TQC3721 suspension for inhalation cost, discount & access